Nian-shuang Li

Jiangxi Provincial Key Laboratory Of Digestive Diseases
Nanchang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial.

Tegoprazan and low- or high-dose amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication (TREAT): protocol for a multicenter, open-label, non-inferiority, randomized controlled trial.

Journal: Therapeutic advances in gastroenterology

Published: March 11, 2025

The epidemiological study of family-based Helicobacter pylori screening and its benefits: a cross-sectional study.

The epidemiological study of family-based Helicobacter pylori screening and its benefits: a cross-sectional study.

Journal: Scientific reports

Published: September 16, 2024

Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis.

Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis.

Journal: Oncogene

Published: September 12, 2024

Comparative transcriptomic analysis reveals the molecular changes of acute pancreatitis in experimental models.

Comparative transcriptomic analysis reveals the molecular changes of acute pancreatitis in experimental models.

Journal: World journal of gastroenterology

Published: December 08, 2023

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study.

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study.

Journal: Frontiers in immunology

Published: September 21, 2022

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.

Journal: Helicobacter

Published: June 07, 2022

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.

Journal: Frontiers in cellular and infection microbiology

Published: February 23, 2022

Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.

Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.

Journal: Helicobacter

Published: February 17, 2022

Discovery and Validation of Novel Methylation Markers in Helicobacter pylori-Associated Gastric Cancer.

Discovery and Validation of Novel Methylation Markers in Helicobacter pylori-Associated Gastric Cancer.

Journal: Disease markers

Published: August 11, 2021

Expression and prognostic significance of the DNA damage response pathway and autophagy markers in gastric cancer.

Expression and prognostic significance of the DNA damage response pathway and autophagy markers in gastric cancer.

Journal: Neoplasma

Published: May 15, 2021

Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.

Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.

Journal: Helicobacter

Published: May 10, 2021

Pancreatic necrosis and severity are independent risk factors for pancreatic endocrine insufficiency after acute pancreatitis: A long-term follow-up study.

Pancreatic necrosis and severity are independent risk factors for pancreatic endocrine insufficiency after acute pancreatitis: A long-term follow-up study.

Journal: World journal of gastroenterology

Published: January 22, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026